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Purpose: Frequent exacerbations which are both costly and potentially life-threatening are 
a major concern to patients with chronic obstructive pulmonary disease (COPD), despite the 
availability of several treatment options. This study aimed to assess the lifetime costs and 
outcomes associated with alternative treatment regimens for patients with severe COPD in the 
UK setting.
Patients and methods: A Markov cohort model was developed to predict lifetime costs, 
outcomes, and cost-effectiveness of various combinations of a long-acting muscarinic antagonist 
(LAMA), a long-acting beta agonist (LABA), an inhaled corticosteroid (ICS), and roflumilast 
in a fully incremental analysis. Patients willing and able to take ICS, and those refusing or 
intolerant to ICS were analyzed separately. Efficacy was expressed as relative rate ratios 
of COPD exacerbation associated with alternative treatment regimens, taken from a mixed 
treatment comparison. The analysis was conducted from the UK National Health Service (NHS) 
perspective. Parameter uncertainty was explored using one-way and probabilistic sensitivity 
analysis.
Results: Based on the results of the fully incremental analysis a cost-effectiveness frontier 
was determined, indicating those treatment regimens which represent the most cost-effective 
use of NHS resources. For ICS-tolerant patients the cost-effectiveness frontier suggested 
LAMA as initial treatment. Where patients continue to exacerbate and additional therapy is 
required, LAMA + LABA/ICS can be a cost-effective option, followed by LAMA + LABA/
ICS + roflumilast (incremental cost-effectiveness ratio [ICER] versus LAMA + LABA/ICS: 
£16,566 per quality-adjusted life-year [QALY] gained). The ICER in ICS-intolerant patients, 
comparing LAMA + LABA + roflumilast versus LAMA + LABA, was £13,764/QALY 
gained. The relative rate ratio of exacerbations was identified as the primary driver of cost-
effectiveness.
Conclusion: The treatment algorithm recommended in UK clinical practice represents a cost-
effective approach for the management of COPD. The addition of roflumilast to the standard of 
care regimens is a clinical and cost-effective treatment option for patients with severe COPD, 
who continue to exacerbate despite existing bronchodilator therapy.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory illness 
characterized by nonreversible airflow limitation and exacerbations. COPD is 
  predominantly caused by tobacco smoke and is a major cause of morbidity and 
mortality worldwide, with an adult (aged $40 years) population prevalence in 
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the region of 10%.1 Based on 2009/2010 data from the 
Quality and Outcomes Framework, there were 861,341 
and 62,744 patients with diagnosed COPD in England and 
Wales, respectively (924,085 in total).2,3 Consequently, the 
treatment and management of COPD has implications not 
only for patients but also for health care providers due to the 
significant burden it places on health care budgets.
The most common symptom of COPD is a shortness 
of breath caused by the narrowing of the airways, but the 
major burden of the disease can be attributed to exacerba-
tions, which are events characterized by an increase in the 
frequency and intensity of symptoms such as dyspnea, cough, 
and sputum production. Exacerbations are important events 
as they have a significant impact on patients’ quality of life 
and also may lead to an increased risk of mortality.4
Exacerbations also have an economic impact due to 
an increase in health care resource use for disease man-
agement and treatment of exacerbations, especially when 
hospitalization is required. The reduction of COPD exac-
erbations, therefore, represents an important goal of COPD 
therapy, both for improvement of patients’ quality of life and 
for efficient use of limited health care resources.
The Global Initiative for Chronic Obstructive Lung 
  Disease (GOLD) system classifies four COPD stages, based 
on the level of post-bronchodilator forced expiratory volume 
achieved in one second, as a percentage predicted of that 
for the general population (forced expiratory volume in 
1   second [FEV1]% predicted): mild (FEV1 $ 80%);   moderate 
(FEV1 50%–79%); severe (FEV1 30%–49%); very severe 
(FEV1 , 30%).5
In the UK, the recent clinical guidelines from the 
National Institute for Health and Clinical Excellence (NICE)6 
recommend alternative treatment approaches, depending 
on the level of FEV1 as a percentage of that predicted for 
the general population. For patients with FEV1 , 50% 
predicted who continue to exacerbate or experience persistent 
breathlessness, the guideline recommends treatment with 
either a long-acting muscarinic antagonist (LAMA), or 
combination treatment with a long-acting beta agonist and 
inhaled corticosteroid (LABA/ICS). If ICS is declined or 
not tolerated by patients, a combination of LABA + LAMA 
should be considered. When a patient continues to 
experience persistent exacerbations or remains breathless, 
LAMA + LABA/ICS is the recommended treatment regimen. 
The NICE guidelines were developed prior to the approval 
of roflumilast by the European Medicines Agency (EMEA) 
in July 2010,7 and therefore, no recommendations on this 
agent were incorporated in the guidelines.
Despite the range of available therapies to manage 
COPD, there is still an unmet need for patients with 
severe and very severe COPD who continue to exacerbate. 
A recent study (ECLIPSE),8 which aimed to investigate 
novel endpoints in COPD disease progression and provide 
a greater insight into patient needs, included an evaluation 
of the proportion of patients with two or more exacerbations 
(requiring antibiotics, corticosteroids, or both, or requiring 
hospitalization) in the last 12 months. The study findings 
suggested that approximately a third of patients with severe 
COPD and almost half of patients with very severe COPD 
had two or more exacerbations per year.8 As more than half 
the study population consisted of patients with severe and 
very severe COPD, this study has confirmed a significant 
unmet need in the management of COPD for both patients 
and health care providers.
Roflumilast is an oral, once-daily selective phosphodi-
esterase-4 inhibitor with a broad range of anti-inflammatory 
actions, which has recently received a license for use 
as maintenance treatment for COPD as an add-on to 
bronchodilators. As proven in clinical trials, roflumilast 
reduced the rate of exacerbations in patients with severe 
airflow obstruction and a history of frequent exacerbations, 
whose COPD is associated with chronic bronchitis.9–12 The 
  objective of this study was to estimate the lifetime cost and 
health outcomes associated with the different treatment 
options available for the management of severe COPD in 
the UK setting in a fully incremental cost-effectiveness 
analysis.
Materials and methods
Model structure and cohort
A cohort state-transition Markov model was constructed to 
estimate the lifetime cost and health outcomes of adding 
roflumilast to therapeutic regimens in patients with severe 
and very severe COPD, associated with chronic bronchitis, 
who have a history of frequent exacerbations and continue 
to exacerbate, despite existing bronchodilator therapy.
Markov cohort models, which consider cohorts of patients 
and are frequently used in cost-effectiveness analyses, are 
particularly useful in the modeling of chronic disease, as 
long term costs and outcomes can be estimated by running 
the model for a large number of cycles (known as Markov 
cycles). Patients move between mutually exclusive health 
states in the model based on a set of transition probabilities, 
which are assigned over a discrete period of time (matching 
the Markov cycle length). For each health state a certain cost 
and health outcome is specified.13
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The Markov model developed for this analysis was 
implemented in TreeAge Pro Suite 2009 (TreeAge Software 
Inc, Williamstown, MA) with a Microsoft® Office Excel 2003 
(Microsoft Corporation, Redmond, WA) front-end and was 
based on a published COPD model.14 The relative rate ratios 
(RRRs) of exacerbation for alternative treatment regimens 
were calculated based on the results of a recently published 
mixed treatment comparison (MTC).15 Using the complete 
set of RRRs, this analysis was the first to simultaneously 
compare various treatment regimens commonly used for 
the management of COPD, via a fully incremental analysis. 
Furthermore, where earlier published models compared 
alternative treatment regimens used at a defined stage in 
the treatment pathway, the current model allowed patients 
to progress from a first-line to a second-line treatment regi-
men, simulating escalation in the COPD treatment regimen 
when a patient continues to exacerbate. The transition from 
a first-line to second-line treatment regimen was determined 
by the average time on the first-line regimen, assumed to be 
1 year in the base case.
The model included five Markov states: severe COPD, 
first-line regimen (S1); severe COPD, second-line regimen 
(S2); very severe COPD, first-line regimen (VS1); very severe 
COPD, second-line regimen (VS2); and death   (Figure 1). 
A detailed model diagram representing transitions is 
  presented in the Appendix (Figure A1).
The S1 health state represents patients with severe COPD, 
who continued to exacerbate, despite their current treatment 
regimen. The S2 health state corresponds to patients with 
severe COPD who initially received first-line treatment, but 
continued to exacerbate, or remained breathless on the first-
line therapy. It was assumed that these patients were switched 
to a second-line regimen. The VS1 health state describes 
patients who were on a first-line treatment regimen and pro-
gressed from severe to very severe COPD, while remaining on 
first-line treatment. The VS2 health state represents: (a) patients 
who were on a first-line treatment regimen in the very severe 
COPD state (VS1), and who were then switched to a second-
line regimen; (b) patients who were on a second-line treatment 
in the severe COPD state (S2), and then progressed to very 
severe COPD, continuing the second-line treatment, and; 
(c) patients initially in the S1 health state, who were switched 
to a second-line treatment regimen upon disease progression 
to very severe COPD (this transition was not modeled in the 
base case, but explored in scenario analysis F). As mentioned 
above, a change from first- to second-line treatment depended 
on the average time on the first-line regimen and was not 
explicitly linked to the events of exacerbation. The severe (S1 
and S2) and very severe (VS1 and VS2) COPD health states 
are based on the definition of severity by GOLD criteria,5 
ie, using postbronchodilator FEV1% predicted, relative to a 
general (non-COPD) population.16
The Markov state ‘Death’ included mortality, modeled 
using a combination of background mortality from UK life 
tables adjusted to the standardized mortality ratio (SMR) for 
COPD, and mortality due to hospital-treated exacerbations. 
The hospital case fatality rate (CFR), ie, the percentage of 
patients who died during a hospital-treated exacerbation 
amounted to 7.7%, as reported in the UK National Chronic 
Obstructive Pulmonary Disease Audit 2008.17 The audit 
reports data on 9,716 COPD admissions for exacerbations, 
and found that the mortality rate in the 90 days following 
admission was 13.9%, with COPD or complication of COPD 
being the cause of death in 65% of mortality cases. The hos-
pital CFR used in the model assumed that all COPD deaths 
occur during the hospital stay, and within the same cycle as 
the exacerbation. The cycle length in the model was 1 month 
and the time horizon was 30 years.
The mean age of patients in the cohort was 64 years at the 
start of the model. The baseline characteristics of the modeled 
Patients who are switched to a second line regimen upon
disease pregression (explored in a scenario analysis only)
Patients who continue to exacerbate or remain breathless
are switched to a second line regimen
Patients who progress to very severe COPD
S2
S1 VS1
VS2
Start
Patients who die due to background mortality and hospital
mortality
Death
Figure 1 Simplified Markov cohort model structure. 
Note: Arrows represent the possible pathways of the disease course.
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cohort were based on the pooled analysis of the M2–124 and 
M2–125 clinical trials of roflumilast.9
Within each model cycle the patients in the cohort were 
at risk of an exacerbation, which could be community-treated 
or hospital-treated.
Costs were calculated from the perspective of the UK 
National Health Service (NHS). The model estimated total 
costs, life-years (LYs), quality-adjusted life-years (QALYs) 
and exacerbations per patient. A discount rate was applied to 
both costs and outcomes to adjust for differential timing, and 
hence allow a comparison of costs and outcomes in terms of 
a net present value.13 In accordance with the NICE reference 
case, costs and outcomes (LYs, QALYs) were discounted at 
a rate of 3.5% per annum.18
A variety of scenario analyses were conducted to 
investigate the effect of uncertainties in the base case 
assumptions on the model results.
Clinical management of COPD patients  
(pathway in the model)
Costs and health outcomes related to the treatment of COPD 
were simulated for two patient groups: ICS-tolerant patients and 
ICS-intolerant patients (including patients who decline ICS). 
A range of first-line treatments were analyzed for both groups 
(Table 1). As roflumilast is indicated for the maintenance 
treatment of severe COPD (FEV1 post-bronchodilator #50% 
predicted) associated with chronic bronchitis in patients with a 
history of frequent exacerbations as an add-on to bronchodilator 
treatment,7 patients in the model were assumed to continue to 
exacerbate despite current therapy. It was assumed that ICS-
tolerant patients and ICS-intolerant patients would receive 
LAMA + LABA/ICS and LAMA + LABA, respectively, if 
they continued to exacerbate. Such an approach is consistent 
with the current recommendations of NICE CG101,6 and was 
assumed to be common across all first-line treatment options 
included in the model.
COPD progression and transition probabilities
The calculation of the average time a patient spends in a 
particular health state was similar to the methods used and 
published elsewhere.19 The assessed patient population was 
assumed to have severe COPD at baseline, with lung func-
tion in the middle of the severe COPD FEV1% range (40% 
predicted), and continued to exacerbate despite their current 
treatment regimen.
Continuous transition probabilities for progression 
from severe to very severe COPD were calculated as 
the reciprocal of the estimated average time (T) in the severe 
COPD states (S1 and S2), and based on the rate of decline 
in lung volume in patients with COPD (0.052 L per year)20 
relative to the natural rate of decline of lung volume in the 
general (non-COPD) population.16 The dotted line in Figure 2 
represents the level of lung function at which FEV1 is 30% 
of the level predicted for the general adult population, at 
any given age. The solid line represents the declining lung 
volume in the modeled cohort of patients who start in severe 
COPD. The predicted intersection of these lines determines 
the average time (T) in the severe COPD states (S1 and S2), 
before progressing to one of the very severe COPD states 
(VS1 and VS2).
Exacerbations
For the purpose of running the fully incremental analysis, 
the rates of exacerbations for each treatment regimen were 
expressed in relative terms to a common reference regimen. 
LAMA + LABA/ICS was used as the reference regimen, with 
an assumed exacerbation rate of 2.0 per patient per year in 
the severe COPD states (community – or hospital-treated). 
The baseline exacerbation rate for the very severe states 
was 2.4 exacerbations per year, calculated by applying the 
ratio of rates of exacerbations in patients with severe and 
very severe COPD from the pooled analysis of the M2–124 
and M2–125 clinical trials of roflumilast to the baseline 
rate of exacerbations in the severe state. The efficacy of 
each treatment regimen versus the reference regimen was 
expressed as an RRR of exacerbations. Due to a lack of direct 
Table 1 COPD therapeutic regimens
ICS-tolerant patients ICS-intolerant patients
First line treatment options
  LABA LABA
  LAMA LAMA
  LABA + roflumilast LABA + roflumilast
  LAMA + roflumilast LAMA + roflumilast
  LAMA + LABA LAMA + LABA
  LAMA + LABA + roflumilast LAMA + LABA + roflumilast
  LABA/ICS
  LABA/ICS + roflumilast
  LAMA + LABA/ICS
  LAMA + LABA/ICS + roflumilast
Second line treatment optionsa
  LAMA + LABA/ICS LAMA + LABA
Note: aIf patients continue to exacerbate, despite existing treatment. 
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  ICS,  inhaled 
corticosteroids;  LABA,  long-acting  beta  agonist;  LAMA,  long-acting  muscarinic 
antagonist.
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Figure 2 Time to disease progression in patients starting in the severe COPD state (illustrative example). 
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second.
Table 2 RRR of exacerbations for treatments versus the common reference regimen (LAMA + LABA/ICS), based on the results of 
the additive mixed treatment comparison15
Treatment Reference 
regimen
RRR of 
exacerbations
95% CI Predicted no of 
exacerbations 
per yeara
LABA 1.65 1.46–1.88 3.29
LAMA 1.41 1.28–1.57 2.83
LABA + roflumilast 1.38 1.16–1.66 2.75
LAMA + roflumilast 1.18 1.01–1.39 2.36
LAMA + LABA Versus 1.22 1.14–1.32 2.44
LABA/ICS LAMA + LABA/ICS 1.35 1.23–1.49 2.70
LAMA + LABA + roflumilast 1.02 0.88–1.18 2.04
LABA/ICS + roflumilast 1.13 0.97–1.33 2.25
LAMA + LABA/ICS 1.00 0.70–1.30 2.00
LAMA + LABA/ICS + roflumilast 0.84 0.74–0.95 1.68
Notes: aPredicted number of exacerbations per year in first line, severe COPD. Calculated relative to the common reference regimen, which is associated with an assumed 
background exacerbation rate of 2.0 exacerbations per year. 
Abbreviations: RRR, relative rate ratio; CI, confidence interval; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids.
clinical trial evidence for several treatment combinations of 
interest, the RRRs of exacerbations were calculated from the 
results of the additive main effects model of the published 
MTC,15 as shown in Table 2. The RRR of exacerbations 
was assumed to be the same in both severe and very severe 
COPD states. It was also assumed that the RRRs can be 
applied to exacerbations without distinguishing between 
community-treated or hospital-treated exacerbations, as the 
data to differentiate between the two types of exacerbations 
were not available. Treatment-related improvements in lung 
function were not considered in the model.
Health-related utilities
Patients’ preferences for a preferred outcome (or health state) 
are represented in the form of utility values, bounded between 
0 (death) and 1 (perfect health). To calculate QALYs, one LY 
was multiplied by the utility value associated with a particu-
lar health state. Two different types of utility were applied in 
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the model: Firstly, utility associated with the severe (0.751) 
and very severe (0.657) COPD health states, which were 
based on EQ-5D data obtained from the pooled analysis of 
the M2–124 and M2–125 clinical trials of roflumilast.9 The 
second type were the annual decrements in utility due to 
a community-treated exacerbation (–0.01) and a hospital-
treated exacerbation (–0.042), which were taken from a 
published study.21 The absolute reduction of utility due to a 
community-treated exacerbation that applies for one year was 
accounted for within the 1-month model cycle by recalculating 
as 0.01 × 12 = 0.12, and deducted from the baseline utilities 
in severe and very severe COPD states. Equally, the absolute 
reduction of utility due to a hospital-treated exacerbation that 
applied for one year was accounted for by recalculating as 
0.042 × 12 = 0.504 and deducted from the baseline utilities.
Adverse events (AEs) related to treatment were assumed 
to be mild and transient in nature, and not to impact health-
related quality of life or costs.
Those patients who did not tolerate ICS were presumed to 
enter the model after an earlier trial of the agent. Subsequent 
discontinuation and related AEs were, therefore, not taken 
into account.
Costs and cost perspective
The perspective of the economic analysis was that of the 
UK NHS payer. Only direct medical costs related to COPD 
treatment were included. Costs were represented across three 
groups: (a) costs of maintenance of patients in the severe and 
very severe COPD states (excluding COPD drugs); (b) costs 
of COPD drugs; and (c) costs of community- and hospital-
treated exacerbations. Drug costs were sourced from the 2011 
British National Formulary (BNF 61).22 Monthly maintenance 
costs for severe and very severe COPD were derived from 
the NHS National Schedule of Reference Costs 2009/1023 
and the published literature.24 Costs of a community-treated 
exacerbation were compiled based on the resource use stated 
in the report by the GOLD Strategy Group,5 and combined 
with cost data from the NHS Reference Costs,23 the Personal 
Social Services Research Unit 201025 and the BNF 61.22 In 
order to calculate the costs of a hospital-treated exacerbation, 
costs for relevant COPD-related health care resource groups 
(HRGs) were weighted by the reported annual number of 
episodes, with data being taken from the NHS Reference 
Costs.23 Further, it was assumed that 90% of patients would 
arrive at the hospital by ambulance. Therefore 90% of the 
HRG cost for ambulance transportation was added to the 
weighted COPD HRG costs. A summary of the costs per 
model cycle and per exacerbation are presented in Table 3 
whereas tables with detailed calculation are provided in the 
appendix (Tables A1 and A2).
Results
Two fully incremental analyses were performed separately 
for ICS-tolerant and ICS-intolerant COPD patients. In the 
analysis the total costs, LYs, QALYs, and the number 
of exacerbations per patient were calculated for each 
treatment over a time horizon of 30 years (lifetime analysis). 
Table 4 shows the results for both populations.
Table 3 Costs per model cycle (summary)
Cost component Costs per cycle   
in GBP
Roflumilast (Daxas®, Nycomed, Zurich, Switzerland)     38.23
LABA     29.67
  Salmeterol (Serevent® Evohaler®, Accuhaler®, and Diskhaler®, GlaxoSmithKline, Brentford, UK)
LAMA     32.33
  Tiotropium (Spiriva®, Boehringer Ingelheim, Ingelheim, Germany)
LABA/ICS     41.49
  Salmeterol/fluticasone (Seretide® 500 Accuhaler, GlaxoSmithKline)
Maintenance, severe COPD     48.33
  Includes outpatient visit respiratory physician, spirometry, influenza vaccination and oxygen therapy
Maintenance, very severe COPD     150.05
  Includes outpatient visit respiratory physician, spirometry, influenza vaccination and oxygen therapy
Community-treated exacerbation     73.56
  Includes general practitioner (consultation lasting 11.7 minutes), Accident & Emergency
  services (not admitted), prednisolone and co-amoxiclav
Hospital-treated exacerbation 1,346.63
  Includes HRG codes DZ21A-H, DZ21J-K and ambulance transportation
Abbreviations: GBP, British pound; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids; COPD, chronic obstructive 
pulmonary disease; HRG, Healthcare Resource Group.
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Based on the results of the fully incremental analyses, 
total costs and total QALYs obtained for each treatment 
were plotted on a single graph (a cost-effectiveness plane), 
and were used to generate a cost-effectiveness frontier. The 
frontier indicates those treatment regimens which represent 
the most cost-effective use of NHS resources, ie, where 
QALY-yield is maximized for a given level of cost, or where 
cost is minimized for a given level of QALY-yield. Any point 
above, or to the left of the frontier represents an inefficient 
use of resources as higher benefit can be achieved at equal 
or lower costs. Such points are referred to as being “domi-
nated”, either by direct dominance (being more costly and 
less effective than a comparator), or by extended dominance 
(where the ICER for a particular treatment is higher than the 
next most effective treatment).26
For ICS-tolerant patients (Figure 3A) the cost-effec-
tiveness frontier analysis suggested starting patients on a 
first-line treatment with LABA or LAMA. For patients who 
continue to exacerbate, LAMA + LABA/ICS presents a cost-
effective option for a second-line treatment (versus LAMA), 
followed by LAMA + LABA/ICS + roflumilast (versus 
LAMA + LABA/ICS). The remaining treatment options are 
either excluded due to direct or extended dominance.
The cost-effectiveness frontier analysis for ICS-intolerant 
patients (Figure 3B) suggests starting patients on LABA or 
LAMA. If patients continue to exacerbate, LAMA + LABA 
is a cost-effective second-line option, followed by 
LAMA + LABA + roflumilast (versus LAMA + LABA).
As with the results of the analysis of patients who are 
able to use ICS, these results are in line with the escalation 
of treatment recommended in NICE CG101.6 Further, for 
both patient groups, the results suggest the use of roflumilast 
in addition to the standard of care (LAMA + LABA/ICS or 
LAMA + LABA, respectively).
Based on the cost-effectiveness frontiers, two com-
parisons of particular interest were selected: LABA/
ICS + LAMA + roflumilast versus LABA/ICS + LAMA 
for ICS-tolerant patients and LABA + LAMA + roflumilast 
versus LABA + LAMA for ICS-intolerant patients. These 
comparisons of interest were subject to further investiga-
tion as they are likely to indicate the most common uses of 
roflumilast in clinical practice, within each patient group. 
Extensive sensitivity analyses were also conducted for these 
comparisons.
As presented in Table 5, LAMA + LABA/ICS + roflumi-
last versus LAMA + LABA/ICS yielded an ICER of £16,566/
QALY gained in ICS-tolerant patients and would therefore 
normally be considered as cost-effective when applying com-
monly accepted thresholds for cost-effectiveness by NICE 
(£20,000 to £30,000 per QALY gained).18 The comparison 
of LAMA + LABA + roflumilast versus LAMA + LABA 
for ICS-intolerant patients yielded an ICER of £13,764/
QALY gained.
Sensitivity and scenario analyses
To examine the impact of parameter uncertainties on the results 
of the analyses, probabilistic sensitivity analysis (PSA) was 
performed for both key comparisons of interest. Appropriate 
distributions were assigned to key model parameters and 
1000 simulations were run. Results of the simulations for 
ICS-tolerant patients are presented as an incremental cost-
effectiveness scatter-plot (Figure 4A) and cost-effectiveness 
acceptability curve (CEAC), which suggests that the 
probability of LAMA + LABA/ICS + roflumilast being 
Table 4 Results of fully incremental cost-effectiveness analysis (base case)
Treatment Costs in GBP Exacerbationsa LYs QALYs
ICS- 
tolerant
ICS- 
intolerant
ICS- 
tolerant
ICS- 
intolerant
ICS- 
tolerant
ICS- 
intolerant
ICS- 
tolerant
ICS-
intolerant
LABA 22,342 21,477 23.48 26.67 8.06 7.75 5.39 5.13
LAMA 22,370 21,500 23.16 26.37 8.10 7.79 5.42 5.17
LABA + roflumilast 22,749 21,879 23.11 26.32 8.11 7.79 5.43 5.17
LAMA + roflumilast 22,779 21,905 22.84 26.06 8.14 7.83 5.46 5.20
LAMA + LABA 22,687 21,814 22.89 26.11 8.14 7.82 5.45 5.19
LAMA + LABA + roflumilast 23,100 22,222 22.61 25.85 8.18 7.86 5.48 5.22
LABA/ICS 22,468 – 23.07 – 8.11 – 5.43 –
LABA/ICS + roflumilast 22,878 – 22.76 – 8.16 – 5.46 –
LAMA + LABA/ICS 22,816 – 22.58 – 8.18 – 5.48 –
LAMA + LABA/ICS + 
roflumilast
23,230 – 22.35 – 8.21 – 5.51 –
Note: aExacerbation rates were not discounted. 
Abbreviations: GBP, British pound; LY, life year; QALY, quality-adjusted life year; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic 
antagonist.
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Figure 3 Cost-effectiveness-frontier analysis for ICS-tolerant patients (A) and ICS-intolerant patients (B).
Abbreviations: GBP, British pound; QALY, quality-adjusted life year; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids.
cost-effective versus LAMA + LABA/ICS exceeds 80%, at 
a willingness-to-pay £30,000 per QALY gained (Figure 4B). 
The PSA for ICS-intolerant patients provided similar results 
(analysis not presented).
In order to test the sensitivity of the base case ICER 
to uncertainties in individual model parameters, one-way 
sensitivity analysis (OWSA) was performed. In the OWSA, 
plausible ranges of different model parameters were first 
identified, using the boundaries of the 95% confidence inter-
vals where possible. In separate model runs, each parameter 
in turn was set first at its upper estimate and then at its lower 
estimate while the remaining variables were set at their base 
case values.
The tornado diagram depicts the variation of the ICER 
(£/QALY gained) of LAMA + LABA/ICS + roflumilast 
versus LAMA + LABA/ICS, from the base case value 
of £16,566/QALY gained, at lower and upper estimate 
of the value of each parameter. The key drivers of 
cost-effectiveness for ICS-tolerant patients were the relative 
rate of exacerbations between the assessed treatment regi-
mens versus the common reference regimen (Figure 5). The 
OWSA for ICS-intolerant patients provided similar results, 
with the ICER showing greatest sensitivity to change in the 
relative rate of exacerbation between the assessed treatment 
regimen versus the common reference regimen (analysis 
not presented).
The effect of changes in the assumptions incorporated 
in the base case on model results were evaluated in various 
scenario analyses, focusing on the comparisons of interest.
Scenario analysis A: The background exacerbation rate 
(ie, the number of exacerbations per year in the severe COPD 
state for the common reference regimen [LAMA + LABA/
ICS]) was adjusted from a base case value of 2 exacerbations 
to 1 and 3 exacerbations.
Scenario analysis B: Incorporation of a change in lung 
function of + 46 mL with the roflumilast regimens, relative 
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Table 5 Results for comparisons of interest (base case)
Outcomes ICER
Costs 
in GBP
LYs QALYs GBP per 
LY gained
GBP per 
QALY gained
ICS-tolerant patients
  LAMA + LABA/ICS + roflumilast 23,230 8.21 5.51
  LAMA + LABA/ICS 22,816 8.18 5.48
Incrementa     414 0.03 0.03 13,422 16,566
ICS-intolerant patients
  LAMA + LABA + roflumilast 22,222 7.86 5.22
  LAMA + LABA 21,814 7.82 5.19
Incrementb       408 0.04 0.03 11,156 13,764
Notes: aLAMA + LABA/ICS + roflumilast minus LAMA + LABA/ICS; bLAMA + LABA + roflumilast minus LAMA + LABA. 
Abbreviations: GBP, British pound; LY, life year; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; ICS, inhaled corticosteroids; LABA, long-acting 
beta agonist; LAMA, long-acting muscarinic antagonist.
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Figure 4 Incremental cost-effectiveness scatter plot (A) and CEAC (B), LAMA + LABA/ICS + roflumilast versus LAMA + LABA/ICS, 1000 runs. 
Abbreviations: GBP, British pound; QALY, quality-adjusted life year; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids.
to the common reference regimen, based on results from 
the subgroup of patients who received LABA + roflumilast 
in the M2–124 and M2–125 clinical trials10 (base case: 
no lung function benefit). The duration of the lung 
function benefit was assumed to be 1 year. A lung function 
improvement would be expected to increase the time spent 
in a particular state, with resultant cost savings and quality 
of life benefit.
Scenario analysis C: Time on first-line therapy was 
adjusted to 0.5 years and 2 years (base case: 1 year).
Scenario analysis D: Patients remained on first-line 
therapy for the duration of the model, including those on 
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16. Utility decrement due to a hospital exacerbation (0.4, 0.504, 0.6) 
17. Cost of maintenance of patients with severe COPD (24.16, 48.33, 72.49) 
18. Proportion of hospital treated exacerbations in very severe state (0.195, 0.244, 0.293) 
19. Mean height of males (165, 171, 175) 
20. Mean height of females (155, 162, 170) 
21. Adverse events costs associated with DAXAS treatment (0, 0, 36.8) 
22. Utility loss associated with an adverse event (0, 0, 0.006) 
Expected ICER at lower
estimate 
Expected ICER at upper
estimate 
Figure 5 Tornado diagram, LAMA + LABA/ICS + roflumilast versus LAMA + LABA/ICS. 
Note: The diagram depicts the variation of the ICER (GBP per QALY gained), from the base case value of £16,566/QALY gained, at lower and upper estimate of the value 
of each parameter. The middle of the tornado diagram corresponds to the base case ICER; the grey bars represent the cost-effectiveness at low estimate of each parameter 
and the black bars at high estimate.
Abbreviations:  LABA,  long-acting  beta  agonist;  LAMA,  long-acting  muscarinic  antagonist;  ICS,  inhaled  corticosteroids;  ICER,  incremental  cost-effectiveness  ratio;   
GBP, British pound; QALY, quality-adjusted life year.
the comparator regimens (base case: patients were assumed 
to receive a second-line treatment which was common to 
all patients).
Scenario analysis E: Patients started treatment in very 
severe COPD health state (base case: severe COPD).
Scenario analysis F: Treatment regimen was switched 
following progression from severe to very severe COPD 
(base case: Switch from a first-line treatment regimen to a 
second-line regimen occurred 1 year after initiation of the 
first-line treatment regimen).
A summary of results for the scenario analyses within 
ICS-tolerant and ICS-intolerant patients for the comparison 
of interest is presented in Tables 6 and 7, respectively.
Results of the scenario analyses in both   populations 
showed that the base case results were sensitive to 
changes in assumptions regarding the baseline rate of 
  exacerbations for the common reference regimen in the 
severe COPD states (scenario A) and also the inclusion of 
lung function benefit (scenario B). As exacerbations are the 
primary efficacy input used in the model, and changes in 
lung function have an impact on disease progression (and 
hence cost and quality of life), it would be expected that these 
parameters would impact model results.
The base case assumption of patients moving to a second-
line treatment after 1 year may vary in clinical practice, but 
scenario C showed that results are not sensitive to adjustment 
in this assumption. This is because simultaneously switching 
patients to a common second-line treatment regimen removes 
potential differences in benefits and costs between the 
initial treatment regimens being compared. Analyses also 
demonstrated the assumed second-line treatment regimen 
(scenario D), patients starting in the very severe COPD state 
(scenario E), and the assumption of switch to second-line 
therapy upon disease progression (scenario F).
Discussion
COPD continues to be a significant burden to health care 
systems around the world, despite the availability of multiple 
treatment options. In particular there remains an unmet need 
for ICS-tolerant and ICS-intolerant patients with severe 
COPD who are inadequately controlled on triple therapy 
(LAMA + LABA/ICS) and dual therapy (LAMA + LABA), 
respectively. As such it is important to understand the 
cost-effectiveness of different treatment options in order 
to optimize health outcomes to most efficiently use health 
care resources.
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This study has employed standard best practice in 
health economic modeling and analysis to examine the 
cost-effectiveness of various treatment options in a fully 
incremental analysis.
The model structure was based on methods previously 
used in other COPD cost-effectiveness modeling studies, with 
regard to the definition of health states, method for calculation 
of disease progression, and modeling of mortality.19 However, 
to our knowledge, this study represents the first fully incre-
mental analysis of commonly used COPD treatments which 
has been reported in the literature.
Two fully incremental analyses were performed for 
patients with severe COPD: one for patients able to receive 
ICS, and a second for patients who do not tolerate or decline 
ICS. In the analysis for those patients able to receive ICS, 
the cost-effectiveness frontier suggests to start patients on 
a first-line treatment with LABA or LAMA. For those who 
continue to exacerbate, LAMA + LABA/ICS presents a 
cost-effective option for a second-line treatment, followed 
by LAMA + LABA/ICS + roflumilast. The addition of 
roflumilast to LAMA + LABA/ICS is associated with an 
ICER of £16,566 per QALY gained.
Table 6 Results for scenario analyses, ICS-tolerant patients
Scenario Costs in GBPa QALYsa ICER (GBP per 
QALY gained)
LAMA + 
LABA/ICS
LAMA + 
LABA/ICS + 
roflumilast
LAMA + 
LABA/ICS
LAMA + 
LABA/ICS + 
roflumilast
LAMA + LABA/ICS + 
roflumilast versus 
LAMA + LABA/ICS
Base case 22,816 23,230 5.4839 5.5089 16,566
A) Baseline number of exacerbations = 1 22,464 22,881 6.2402 6.2543 29,581
    Baseline number of exacerbations = 3 23,028 23,440 4.8638 4.8975 12,259
B)    Incorporation of lung function  
benefit
22,816 23,170 5.4839 5.5249   8,617
C) Time on first line = 0.5 years 22,816 23,021 5.4839 5.4967 16,068
    Time on first line = 2 years 22,816 23,597 5.4839 5.5309 16,628
D) Patients remain on first line 22,816 26,602 5.4839 5.7111 16,661
E)     Patients start in very severe  
COPD
26,444 26,883 4.4922 4.5279 12,310
F)   Treatment switch following  
disease progression
22,816 24,725 5.4839 5.5834 19,186
Note: aRounded values. 
Abbreviations: GBP, British pound; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; 
LAMA, long-acting muscarinic antagonist.
Table 7 Results for scenario analyses, ICS-intolerant patients
Scenario Costs in GBPa QALYsa ICER (GBP per 
QALY gained)
LAMA +  
LABA
LAMA + LABA + 
roflumilast
LAMA +  
LABA
LAMA + LABA + 
roflumilast
LAMA + LABA + 
roflumilast versus 
LAMA + LABA
Base case 21,814 22,222 5.1948 5.2244 13,764
A)  Baseline number of exacerbations = 1 21,296 21,710 6.0590 6.0761 24,186
     Baseline number of exacerbations = 3 22,128 22,532 4.5114 4.5505 10,321
B)     Incorporation of lung function  
benefit
21,814 22,162 5.1948 5.2410   7,552
C)  Time on first line = 0.5 years 21,814 22,016 5.1948 5.2100 13,336
   Time on first line = 2 years 21,814 22,581 5.1948 5.2503 13,826
D) Patients remain on first line 21,814 25,408 5.1948 5.4563 13,744
E)     Patients start in very severe  
COPD
25,386 25,822 4.1721 4.2137 10,479
F)      Treatment switch following  
disease progression
21,814 23,663 5.1948 5.3123 15,736
Note: aRounded values. 
Abbreviations: GBP, British pound; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; LABA, long-acting beta agonist; LAMA, long-acting 
muscarinic antagonist.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
193
Cost-effectiveness of COPD-treatments in the UKInternational Journal of COPD 2012:7
The analysis for patients who do not tolerate or decline 
ICS also identified the optimal place for roflumilast as being 
an add-on to the current standard of care (LAMA + LABA), 
where the addition of roflumilast to LAMA + LABA is 
associated with an ICER of £13,764 per QALY gained.
These suggested positions in the treatment pathway are 
in line with the algorithm recommended in NICE Guidelines 
CG101, and identify an optimal positioning for roflumilast 
as an add-on to the currently recommended standard of care. 
A range of sensitivity and scenario analyses were also per-
formed on the comparisons, with the majority continuing to 
demonstrate the cost-effectiveness of the agent.
The strengths of this analysis include a model which was 
developed in line with the current best practice in the field of 
economic modeling of COPD treatments. Additional func-
tionality allowed for a fully incremental analysis and treat-
ment sequencing, which may be regarded as useful advances 
in this area. In addition, clinical parameters for the RRRs for 
exacerbations were derived from a recently published MTC, 
which assessed the breadth of available evidence.
Limitations of the analysis are principally related to the 
lack of published data, with no head-to-head clinical trial 
evidence being available for certain treatment regimens. 
Whilst the availability of the additive MTC15 allowed these 
comparisons to be made, this does introduce uncertainty 
into the analysis, as illustrated by the OWSA and results 
for changes in the exacerbation rates. Furthermore, studies 
M2–124 and M2–125 were not powered to demonstrate the 
reduction of risk of severe exacerbations alone.9 The economic 
model estimated the number of severe exacerbations as a 
proportion of all exacerbations and assumed that exacerbation 
reduction translates into a proportional reduction of both 
community- and hospital-treated exacerbations. Very few 
studies reported the change in FEV1 between the treatments 
of interest, meaning that it was not possible to conduct an 
MTC for this endpoint. There is no robust analytical approach 
to estimate the one-off lung function benefit between 
therapies. The primary aim of COPD treatment is, however, 
the prevention of exacerbations, which was the key clinical 
input in this analysis. As many of the limitations of this study 
are related to the lack of available data, further research is 
required to improve the precision of any future analysis.
Despite these limitations, this is the most up-to-date cost-
effectiveness analysis of treatments for COPD, and the first 
to consider treatments within a fully incremental modeling 
framework. The results support the treatment pathway which 
is currently recommended in the NICE COPD Clinical 
Guideline, and identifies the value of roflumilast as an add-on 
treatment to the current standards of care.
Conclusion
Overall these analyses suggest that the treatment algorithm 
recommended in UK clinical practice represents a cost-
effective approach for the management of COPD. The 
addition of roflumilast to the currently recommended 
standards of care is a clinical and cost-effective treatment 
strategy for patients with severe COPD who continue to 
exacerbate despite existing bronchodilator therapy.
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Figure A1 Detailed model scheme.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
196
Hertel et alInternational Journal of COPD 2012:7
Table A1 Outpatient costs for COPD drugs, maintenance of severe and very severe COPD, and community-treated exacerbation
Cost category Unit cost in GBP Resource use Costs  
in GBP
Calculation/reference
COPD drugs
Roflumilast 
    (Daxas®  
Nycomed, Zurich,  
Switzerland
30-day pack = £37.71 38.23 Costs per model cycle. Based on the cost 
of 30-day pack of £37.71, adjusted to the 
average days per month of 365/12. Unit  
cost source:22
LABA
    Salmeterol 
(Serevent®  
Evohaler®, Accuhaler®  
and Diskhaler®  
GlaxoSmithKline,  
Brentford, UK)
Evohaler: 25 mcg per dose, 
120-dose unit = £29.26;
Accuhaler: 50 mcg per dose,
60-dose unit = £29.26;
Diskhaler: 50 mcg per disk,
60-disk pack, with device =
£35.79; 60-disk refill pack =
£35.15
50 mcg twice daily 29.67 Costs per model cycle: (£29.26/30)*(365/12).
Calculated cost for LABA assumes all items 
are prescribed as the Accuhaler or Evohaler, 
which are associated with a lower daily 
treatment cost than the Diskhaler (or refills). 
Unit cost source:22
LAMA
    Tiotropium 
(Spiriva®, Boehringer  
Ingelheim, Ingelheim,  
Germany)
30-cap refill pack (18 mcg 
per cap) = £31.89; 30-cap 
pack (18 mcg per cap) with 
HandiHaler device = £34.87
18 mcg once daily 32.33 Costs per model cycle: (£31.89/30)*(365/12).
Calculated cost for LAMA assumes all items 
are prescribed as refill packs, 
which are associated with a lower daily 
treatment cost than when combined 
with the HandiHaler device. Unit  
cost source:22
LABA/ICS
    Salmeterol/ 
fluticasone 
(Seretide® 500 Accuhaler 
GlaxoSmithKline)
50 mcg salmeterol  
(as xinafoate) + 500 mcg 
fluticasone per puff, 60-dose
Accuhaler = £40.92
1 dose of Seretide 
500, twice daily
41.49 Costs per model cycle: (£40.92/30)*(365/12).
Unit cost source:22
Maintenance, severe COPD
Outpatient visit  
respiratory physician
 
Spirometry
 
 
 
Influenza vaccination
 
 
 
 
Oxygen therapy 
 
 
 
 
Average monthly cost
131.12
 
 
49.98
 
 
 
4.15
 
 
 
 
14.70
Twice a year
 
 
Twice a year
 
 
 
75% of patients
annual vaccination
 
 
 
1.22 days 
 
 
 
 
21.85
 
 
     8.33
 
 
 
     0.26
 
 
 
 
17.89
 
 
 
 
48.33
National schedule of reference costs 2009/10.23
Consultant-led face to face attendance/
respiratory medicine. Service code 340
National schedule of reference costs 2009/10.23 
NHS Trusts and PCTs combined direct 
access: diagnostic services/spirometry test 
and bronchodilator response test. DA07
Injection, suspension of propiolactone-
inactivated influenza virus (surface antigen, 
grown in fertilized hens’ eggs), net price  
0.5-mL prefilled syringe = £4.15. Unit  
cost source:22
Cost per day of 12.64 Euro has been inflated 
from 2001 to 2010 values using the Hospital 
and Community Health Services (HCHS) 
pay and price index from the PSSRU27 and 
converted to GBP
Estimates of resource use are based on 
published literature.24 This study was 
conducted in The Netherlands and Canada, 
and resource utilization was assumed to be 
applicable to the UK
Maintenance, very severe COPD
Outpatient visit  
respiratory physician
131.12 Four times a year 43.71 National schedule of reference costs 2009/10.23 
Consultant-led face to face attendance/
respiratory medicine. Service code 340
Spirometry 49.98 Four times a year 16.66 National schedule of reference costs 2009/10.23 
NHS Trusts and PCTs combined direct 
access: diagnostic services/spirometry test 
and bronchodilator response test. DA07
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Table A1 (Continued)
Cost category Unit cost in GBP Resource use Costs  
in GBP
Calculation/reference
Influenza vaccination 4.15 75% of patients  
annual vaccination
     0.26 Injection, suspension of propiolactone-
inactivated influenza virus (surface antigen, 
grown in fertilized hens’ eggs), net price  
0.5-mL prefilled syringe = £4.15.  Unit  
cost source:22
Oxygen therapy 14.70 6.08 days     89.43 Cost per day of 12.64 Euro has been inflated 
from 2001 to 2010 values using 
the Hospital and Community Health Services 
(HCHS) pay and price index from the 
PSSRU27 and converted to GBP.
Average monthly cost 150.05 Estimates of resource use are based on 
published literature.24 This study was 
conducted in the Netherlands and Canada, 
and resource utilization was assumed to be 
applicable to the UK.
Community-treated exacerbation
GP (consultation  
lasting 11.7 minutes)
36.00 1 (Proportion: 2/3)     24.00 Assumption: 2/3 of patients are treated by 
GP (unit cost source:25) and 1/3 of patients 
treated in A & E, ie Accident & Emergency 
services: not leading to hospital admission.
A & E (no admission) 126.78 1 (Proportion: 1/3)     42.26 Currency Code: VB06Z (unit cost source:23).
Prednisolone 30 mg 0.57 7 days 
(Proportion: 1/2)
      2.00 1 × 25 mg tablet and 1 × 5 mg tablet; 
Assumption: 50% have treatment for 7 days 
and 50% have treatment for 14 days. Unit 
cost source:22
Prednisolone 30 mg 0.57 14 days       4.01
(Proportion: 1/2)
Co-amoxiclav 500 mg 0.26 3 days 
(Proportion: 1/2)
      0.39 Resource use source:5. Assumption: 50% 
have treatment for 3 days and 50% have 
treatment for 7 days. Unit cost source:22
Co-amoxiclav 500 mg 0.26 7 days 
(Proportion: 1/2)
      0.91
Average cost of a community-treated exacerbation    73.56
Abbreviations: GBP, British pound; QALY, quality-adjusted life year; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; 
GP, general practitioner.
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Table A2 Inpatient cost of a hospital-treated exacerbation
HRG 
code
HRG description NHS trusts non-elective inpatient HRG data
Long stay Short stay
Activity National average 
unit cost in GBP
Activity National average 
unit cost in GBP
DZ21A COPD or bronchitis with length of stay #1 day discharged home   8,202     747 61,819    391
DZ21B COPD or bronchitis with Intubation with major CC      101 2,306     24    577
DZ21C COPD or bronchitis with Intubation with CC     19 2,171   8    448
DZ21D COPD or bronchitis with Intubation without CC   4 1,725   1    320
DZ21E COPD or bronchitis with NIV without intubation with major CC     3,360 2,280      362    490
DZ21F COPD or bronchitis with NIV without intubation with CC       993 2,099     83    525
DZ21G COPD or bronchitis with NIV without intubation without CC       218 1,724     19    390
DZ21H COPD or bronchitis without NIV without intubation with major CC 34,530 2,029   4,521    424
DZ21J COPD or bronchitis without NIV without intubation with CC 46,986 1,643   4,780    387
DZ21K COPD or bronchitis without NIV without intubation without CC 11,721 1,279   1,276    385
Weighted 
average
1,684.15    393.32
Weighted average estimates per hospitalization    1,158.57
Weighted cost of ambulance transportation    188.06
Average cost of a hospital-treated 
exacerbation
1,346.63
Notes: aCalculated according to the formula: [(sum_activity units × sum_national average unit cost)LONG STAY + (sum_activity units × sum_national average unit cost)SHORT STAY]/
[(sum_activity units)LONG STAY + (sum_activity units)SHORT STAY]. Source:23; bthe cost of ambulance transportation was estimated at £208.95 based on the National Schedule of 
Reference Costs Year: ‘2009/10’ - NHS trusts paramedic services: category B/Amber, service code PS06B (06 breathing problems; breathing difficulty). It was assumed that 
90% of patients would be delivered to hospital by ambulance.23
Abbreviations:  NHS,  National  Health  Service;  HRG,  Healthcare  Resource  Group;  COPD,  chronic  obstructive  pulmonary  disease;  NIV,  Non-invasive  ventilation;   
GBP, British pound; CC, complications and co-morbidities.
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